Novartis Ag

Sandoz Gmbh

Novartis Pharma Gmbh

Bork Balkan

Edwin Bernard Villhauer

Thomas Edward Hughes

David Grenville Holmes

Mahavir Prashad

Piotr Henryk Karpinski

Liladhar Murlidhar Waykole

Raeann Wu

Wolfgang Marterer

Bertrand Sutter

Denis Har

Jean-Claude Bianchi

Massimo Pignone

Doris Stingelin

Eckart Buerger

James Anthony Vivelo

Paul Allen Sutton

Michael John Girgis

Jessica Liang

Robert C Anderson

Howard C Smith

Boerk Balkan

David G Holmes

James D Fraser

Gregory R Bebernitz

Jeffrey W Hughes

Börk Balkan

The present invention relates to salts of (R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane, to methods for making them or their precursors, to pharmaceutical compositions comprising them, and to their use as medicaments.

Salts of aza-bicyclic di-aryl ethers and methods to make them or their precursors

Salts of aza-bicyclic di-aryl ethers and pharmaceuticals thereof

The present invention relates to novel crystalline forms of (4-{4-[5-(6-Trifluoromethyl-pyridin-3-ylamino)-pyridin-2-yl]-phenyl}-cyclohexyl)-acetic acid, sodium and their use in the treatment or prevention of a condition or a disorder associated with DGAT1 activity in animals, particularly humans. It also relates to processes for making such novel crystalline forms.

Crystalline forms of the sodium salt of (4-{4-[5-(6-trifluoromethyl-pyridin-3-ylamino)-pyridin-2-yl]-phenyl}-cyclohexyl)-acetic acid

The invention relates to a method to reduce the hypoglycemic events, especially sever hypoglycemic events resulting from insulin treatment, wherein the patient is treated with a Dipeptidyl peptidase IV inhibitor (DPP-IV inhibitor) or a pharmaceutically acceptable salt thereof.

Use of DPP-IV inhibitor to reduce hypoglycemic events

The invention discloses certain N-(substituted glycyl)-pyrrolidines, pharmaceutical compositions containing said compounds as an active ingredient thereof, and the use of said compounds in inhibiting dipeptidyl peptidase-IV.

N-(substituted glycyl)-pyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV

N-(substituted glycyl)-2 cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV

The present invention relates to a compound of formula (I) ##STR1## wherein R is substituted adamantyl; and n is 0 to 3; in free form or in acid addition salt form. Compounds of formula I inhibit DPP-IV (dipeptidyl-peptidase-IV) activity. They are therefore indicated for use as pharmaceuticals in inhibiting DPP-IV and in the treatment of conditions mediated by DPP-IV, such as non-insulin-dependent diabetes mellitus, arthritis, obesity, osteoporosis and further conditions of impaired glucose tolerance.

N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions

N-(N'-substituted glycyl)-2-cyanopyrrolidines of formula I ##STR1## wherein R is as defined herein. Compounds of formula I inhibit DPP-IV (dipeptidyl-peptidase-IV) activity. They are therefore indicated for use as pharmaceuticals in inhibiting DPP-IV and in the treatment of conditions mediated by DPP-IV, such as non-insulin-dependent diabetes mellitus, arthritis, obesity, osteoporosis and further conditions of impaired glucose tolerance.

Use of N-(substituted glycyl)-2-cyanopyrrolidines in inhibiting

The invention discloses certain N-(substituted glycyl)-4-cyanothiazolidines, pharmaceutical compositions containing said compounds as an active ingredient thereof, and the use of said compounds in inhibiting dipeptidyl peptidase-IV.

N-(substituted glycyl)-4-cyanothiazolidines, pharmaceutical compositions

The invention discloses certain N-(substituted glycyl)-thiazolidines, pharmaceutical compositions containing said compounds as an active ingredient thereof, and the use of said compounds in inhibiting dipeptidyl peptidase-IV.

N-(substituted glycyl)-thiazolidines, pharmaceutical compositions

N-(N'-substituted glycyl)-2-cyanopyrrolidines of formula I ##STR1## Compounds of formula I inhibit DPP-IV (dipeptidyl-peptidase-IV) activity. They are therefore indicated for use as pharmaceuticals in inhibiting DPP-IV and in the treatment of conditions mediated by DPP-IV, such as non-insulin-dependent diabetes mellitus, arthritis, obesity, osteoporosis and further conditions of impaired glucose tolerance.

Compounds of the formula ##STR1## where X.sub.1 and X.sub.2 are independently O or S, and

Phosphinyloxy propanaminium inner salt derivatives

Growing community of inventors

East Hanover, NJ, United States of America

Edwin Bernard Villhauer